Life Science News

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?prid=27579&wire=1
Lead Plaintiff Deadline: June 14, 2022
Class Period: May 7, 2021 - February 25, 2022

Allegations against AUPH include that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Lilium N.V. f/k/a Qell Acquisition Corp. (NASDAQ:LILM)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/lilium-n-v-f-k-a-qell-acquisition-corp-loss-submission-form?prid=27579&wire=1
Lead Plaintiff Deadline: June 17, 2022
Class Period: March 30, 2021 - March 14, 2022

Allegations against LILM include that: (1) Lilium materially overstates the design and capabilities of the Lilium Jet, an electric vertical take-off-and-landing aircraft for use in a new type of high-speed air transport system for people and goods; (2) Lilium materially overstates the likelihood for the Lilium Jet's timely certification; (3) Lilium misrepresents its ability to obtain or create the necessary batteries for the Lilium Jet; (4) the special purpose acquisition company merger would not and did not generate enough cash to commercially launch the Lilium Jet; (5) Qell Acquisition Corp. did not engage in proper due diligence regarding its merger with Lilium GmbH; and (6) as a result, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.

Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (NYSE:LICY)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/li-cycle-holdings-corp-f-k-a-peridot-acquisition-corp-loss-submission-form?prid=27579&wire=1
Lead Plaintiff Deadline: June 20, 2022
Class Period: February 16, 2021 - March 23, 2022

Allegations against LICY include that: (1) Li-Cycle's largest customer, Traxys, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle's product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company's mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company's reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company's gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

The Law Offices of Vincent Wong, Monday, May 23, 2022, Press release picture

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE : The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/702278/SHAREHOLDER-ALERT-AUPH-LILM-LICY-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

News Provided by ACCESSWIRE IA via QuoteMedia

AUP:CA,AUPH

Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy –

Kite's Third Approved Cell Therapy Indication in Europe

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

NDA Resubmission Addresses Issues Related to Vial Compatibility –

If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2022, at 4:30 p.m. EDT.

Cardiol Therapeutics 2022 AGM

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

- By signing the Kigali Declaration, Gilead joins the global community committed to ending neglected tropical diseases by 2030 -

Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declaration is an important milestone for the World Health Organization's 2030 road map which includes global targets to prevent, control and in some cases eliminate 20 diseases and disease groups by 2030.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities

AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact Week of Possibilities is AbbVie's global, in-person volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering

NORTH CHICAGO, Ill. , June 27, 2022 /PRNewswire/ -- AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local communities around the world. From June 27 to July 1 , AbbVie employees will work with trusted community partners to complete hands-on projects, including renovating schools, playgrounds and community centers, to benefit local communities impacting tens of thousands of people.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

"As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry, including the equity capital markets, banking practices and financial transaction experience," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We are delighted to have him join our executive management team and will benefit from his leadership, strategic insights, and guidance as we advance HM43239 and luxeptinib through clinical development toward commercialization."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×